Business
MustGrow Announces Record Q2-2025 Results: $2.8 Million Revenue and 20.9% Gross Profit Margin for the Quarter
Investor Webcast: Thursday, August 28th at 4:00pm ET / 1:00pm PT Register/View Here: https://...
About this update from Mustgrow Biologics Corp.
[{"type":"text","content":"MustGrow Announces Record Q2-2025 Results: $2.8 Million Revenue and 20.9% Gross Profit Margin for the QuarterInvestor Webcast: Thursday, August 28th at 4:00pm ET / 1:00pm PTRegister/View Here: https://us02web.zoom.us/webinar/register/2017556244178/WN_xF4GBBCXThC3_f1GZYAkZgPlease join/register at least 5 minutes prior to the call.Questions emailed to [email protected] will be addressed during the Q&A portion of the webcast.Saskatoon, Saskatchewan--(Newsfile Corp. - August 27, 2025) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the \"Company\" or \"MustGrow\"), a leading provider of biological and regenerative agriculture solutions, is pleased to announce its operating and financial results for the three months ended June 30, 2025. For complete details, please refer to the Q2-2025 Condensed Interim Financial Statements and associated Management's Discussion and Analysis, available on SEDAR+: www.sedarplus.ca or on the Company's website: www.mustgrow.ca.Key Financial Highlights:Sales revenue of $2.8 million was recorded (including $312,832 from sales of TerraSanteTM biofertility product in the U.S.) in Q2-2025 vs. no revenue in Q2-2024Gross profit of $594,718 equating to a 20.9% gross profit margin in Q2-2025 (up from 14.3% in Q1-2025)(1)Cash and equivalents on hand as at June 30, 2025 was $1.8 million with inventory of $1.8 millionNet loss for the three-month period ended June 30, 2025 was $1.1 million and the net loss per share was $0.02 (basic) for the same period\"Our second quarter 2025 showed a gross profit margin improvement over the first quarter end March 31, 2025 resulting from sales of TerraSanteTM biofertility product in the U.S.,\" stated Corey Giasson, President and CEO of MustGrow. \"We sold out of our TerraSanteTM inventory in the U.S. during this second quarter, which was triple our TerraSanteTM sales in all of 2024. The TerraSanteTM initial sales ramp-up has started and we are working on producing more product to meet the growing demand. For our Canadian sales and distribution division, NexusBioAg, Q2 and Q3 are considered the slower 'shoulder season' whereas Q1 and Q4 are traditionally stronger sales periods for Canadian farmers purchasing crop inputs. Margins in this segment have picked up from the first quarter and we are looking to finish the year with a strong Q4.\"The Company continue...